Device Therapy and Cardiac Transplantation for End-Stage Heart Failure

Barry A. Boilson, Eugenia Raichlin, Soon J. Park, Sudhir S. Kushwaha

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The prevalence of heart failure is increasing, and the prognosis of end-stage heart failure remains dismal. The gold-standard therapy in end-stage heart failure remains cardiac transplantation at the present time, but there is a great excess of eligible candidates compared with the number of donor organs. Advances in mechanical support, the development of the left ventricular assist device (LVAD), and the total artificial heart has reduced mortality and morbidity in patients awaiting transplantation, and LVADs are now approved as an strategy for destination therapy. Miniaturization, increased device durability, and complete implantability may render LVADs an option in earlier stages of heart failure, as a bridge to myocardial recovery or even as a viable alternative to transplantation. Alternative strategies under investigation are cell therapy and xenotransplantation. In the present article, current and potential future therapeutic options in end-stage heart failure are reviewed.

Original languageEnglish (US)
Pages (from-to)8-64
Number of pages57
JournalCurrent Problems in Cardiology
Volume35
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Heart Transplantation
Heart Failure
Equipment and Supplies
Transplantation
Miniaturization
Artificial Heart
Therapeutics
Heterologous Transplantation
Heart-Assist Devices
Cell- and Tissue-Based Therapy
Gold
Tissue Donors
Morbidity
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Device Therapy and Cardiac Transplantation for End-Stage Heart Failure. / Boilson, Barry A.; Raichlin, Eugenia; Park, Soon J.; Kushwaha, Sudhir S.

In: Current Problems in Cardiology, Vol. 35, No. 1, 01.2010, p. 8-64.

Research output: Contribution to journalArticle

Boilson, Barry A. ; Raichlin, Eugenia ; Park, Soon J. ; Kushwaha, Sudhir S. / Device Therapy and Cardiac Transplantation for End-Stage Heart Failure. In: Current Problems in Cardiology. 2010 ; Vol. 35, No. 1. pp. 8-64.
@article{5dc9ce9c8f994222ac2a2f0bf64d5733,
title = "Device Therapy and Cardiac Transplantation for End-Stage Heart Failure",
abstract = "The prevalence of heart failure is increasing, and the prognosis of end-stage heart failure remains dismal. The gold-standard therapy in end-stage heart failure remains cardiac transplantation at the present time, but there is a great excess of eligible candidates compared with the number of donor organs. Advances in mechanical support, the development of the left ventricular assist device (LVAD), and the total artificial heart has reduced mortality and morbidity in patients awaiting transplantation, and LVADs are now approved as an strategy for destination therapy. Miniaturization, increased device durability, and complete implantability may render LVADs an option in earlier stages of heart failure, as a bridge to myocardial recovery or even as a viable alternative to transplantation. Alternative strategies under investigation are cell therapy and xenotransplantation. In the present article, current and potential future therapeutic options in end-stage heart failure are reviewed.",
author = "Boilson, {Barry A.} and Eugenia Raichlin and Park, {Soon J.} and Kushwaha, {Sudhir S.}",
year = "2010",
month = "1",
doi = "10.1016/j.cpcardiol.2009.09.001",
language = "English (US)",
volume = "35",
pages = "8--64",
journal = "Current Problems in Cardiology",
issn = "0146-2806",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Device Therapy and Cardiac Transplantation for End-Stage Heart Failure

AU - Boilson, Barry A.

AU - Raichlin, Eugenia

AU - Park, Soon J.

AU - Kushwaha, Sudhir S.

PY - 2010/1

Y1 - 2010/1

N2 - The prevalence of heart failure is increasing, and the prognosis of end-stage heart failure remains dismal. The gold-standard therapy in end-stage heart failure remains cardiac transplantation at the present time, but there is a great excess of eligible candidates compared with the number of donor organs. Advances in mechanical support, the development of the left ventricular assist device (LVAD), and the total artificial heart has reduced mortality and morbidity in patients awaiting transplantation, and LVADs are now approved as an strategy for destination therapy. Miniaturization, increased device durability, and complete implantability may render LVADs an option in earlier stages of heart failure, as a bridge to myocardial recovery or even as a viable alternative to transplantation. Alternative strategies under investigation are cell therapy and xenotransplantation. In the present article, current and potential future therapeutic options in end-stage heart failure are reviewed.

AB - The prevalence of heart failure is increasing, and the prognosis of end-stage heart failure remains dismal. The gold-standard therapy in end-stage heart failure remains cardiac transplantation at the present time, but there is a great excess of eligible candidates compared with the number of donor organs. Advances in mechanical support, the development of the left ventricular assist device (LVAD), and the total artificial heart has reduced mortality and morbidity in patients awaiting transplantation, and LVADs are now approved as an strategy for destination therapy. Miniaturization, increased device durability, and complete implantability may render LVADs an option in earlier stages of heart failure, as a bridge to myocardial recovery or even as a viable alternative to transplantation. Alternative strategies under investigation are cell therapy and xenotransplantation. In the present article, current and potential future therapeutic options in end-stage heart failure are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=70749149441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70749149441&partnerID=8YFLogxK

U2 - 10.1016/j.cpcardiol.2009.09.001

DO - 10.1016/j.cpcardiol.2009.09.001

M3 - Article

VL - 35

SP - 8

EP - 64

JO - Current Problems in Cardiology

JF - Current Problems in Cardiology

SN - 0146-2806

IS - 1

ER -